Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Post by Thejew on May 06, 2019 5:35pm

99 Views

Post# 29716738

Brent

is obviously a shorter and is getting nervous because he knows this is about to bounce back. I can just tell how much anxiety he has by the way he is typing LOL.

There is no way he is wasting that much time "trying to help people" go volunteer at a homeless shelter dude! Ahhaa

How is this a gamble when they are now fully funded for the rest of pHase2 and more, it's at 52 week lows and is showing incredible interim data? This is as close to slam dunk in bio world as it gets!

Bullboard Posts

Pro Women’s Hockey League comes to NHL 25 in December